Patent application number | Description | Published |
20110200632 | ADJUVANTING MATERIAL - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 08-18-2011 |
20140079728 | ADJUVANTING MATERIAL - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 03-20-2014 |
20150307545 | ADJUVANTING MATERIAL - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 10-29-2015 |
Patent application number | Description | Published |
20080233143 | Adjuvanting Material - The present invention provides an adjuvanting material, the adjuvanting material comprising a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group. Further, the present invention provides an immunogenic composition comprising (a) a lipid dendritic cell targeting moiety to which is covalently linked a metal chelating group; (b) an antigen comprising a metal affinity tag; and optionally (c) metal ions, whereby the antigen is linked to the lipid dendritic cell targeting moiety via the interaction between the metal affinity tag and the metal chelating group. | 09-25-2008 |
20090209485 | MODULATING ANGIOGENESIS WITH NOD FACTORS SUCH AS GLUCOSAMINE OLIGOSACCHARIDES - This invention relates to the use of Nod factors and derivatives thereof for the modulation of blood vessel growth and development as well as compositions for modulating angiogenesis. | 08-20-2009 |
20100143456 | MODEL MEMBRANE SYSTEMS - The present invention relates generally to modifying biological and/or synthetic membranes or liposomes, or combinations thereof, for the purpose of altering immunity, or for the targeting of drugs and other agents to a specific cell type or tissue when administered in vivo to achieve a therapeutic effect. Modification of the membranes is achieved by incorporation and/or attachment of metal chelating groups, thereby allowing engraftment of one or more targeting molecules possessing a metal affinity tag, and a targeting of the engrafted membranes to specific cell types or tissues in vivo. The invention, thus, provides a means of modifying the properties of biological and/or synthetic membranes and liposomes for the purpose of altering or enhancing immunity when used as vaccines, or for the targeting of encapsulated/incorporated drugs or other agents to a specific cell type or tissue when administered in vivo, to achieve a therapeutic effect or response, or for modifying a physiological response or biological function. | 06-10-2010 |
20110104173 | INHIBITION OF DEGRADATION OF EXTRACELLULAR MATRIX - This application relates to a method of inhibiting the degradation of an extracellular matrix associated with islet beta cells, said method comprising contacting said extracellular matrix with an effective amount of a heparanase inhibitor. | 05-05-2011 |
20130142864 | IN VIVO TARGETING OF DENDRITIC CELLS - The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections. | 06-06-2013 |
20130143840 | HEPARAN SULFATE REPLACEMENT THERAPY - The present invention relates to a method for inhibiting oxidative damage of islet beta cells in vivo in a subject by administering to the subject a therapeutically effective amount of heparan sulfate capable of protecting islet beta cells from reactive oxygen species or in vitro by exposing isolated islet beta cells, prior to transplantation, to a concentration of heparan sulfate that protects them from reactive oxygen species. | 06-06-2013 |
Patent application number | Description | Published |
20090019598 | Anther specific promoters and uses thereof - The present invention provides as isolated anther specific promoter nucleic acid molecule homologous to the Ta39 promoter of tobacco. Also contemplated are uses of the nucleic acid molecule to direct expression of a heterologous nucleic acid molecule to anther and/or pollen of a plant. | 01-15-2009 |
20090044289 | Nucleic acid molecules and their use in plant sterility - The present invention provides a method for disrupting pollen development in a plant, the method comprising inhibiting the expression of an endogenous nucleic acid molecule which is, under normal conditions, detectably expressed in anther tissue of a plant during pollen formation, and which codes for a protein belonging to the MYB class of DNA binding transcription factors. Particularly, the nucleic acid molecule whose expression is blocked encodes MYB 32 or MYB 103. The invention also provides nucleic acid molecules for use in the method, use of the method in producing male sterile plants and transgenic plants produced in accordance with the method. | 02-12-2009 |
20120185963 | Nucleic Acid Molecules and Their Use in Plant Sterility - The present invention provides a method for disrupting pollen development in a plant, the method comprising inhibiting the expression of an endogenous nucleic acid molecule which is, under normal conditions, detectably expressed in anther tissue of a plant during pollen formation, and which codes for a protein belonging to the MYB class of DNA binding transcription factors. Particularly, the nucleic acid molecule whose expression is blocked encodes MYB 32 or MYB 103. The invention also provides nucleic acid molecules for use in the method, use of the method in producing male sterile plants and transgenic plants produced in accordance with the method. | 07-19-2012 |
20120331579 | TRANSGENIC PLANT MALE STERILITY - The invention relates to a reversible transgenic plant male sterility system wherein the male sterility is induced by amiRNA and a reversible transgenic plant male sterility system comprising a male sterility construct comprising an isolated nucleic acid encoding a precursor amiRNA encoding an amiRNA targeted to a gene involved in pollen development, and a male fertility restorer construct comprising an isolated nucleic acid encoding a mutated copy of the gene involved in pollen development, or multiple copies of said gene involved in pollen development, or a single copy of said gene involved in pollen development under the control of a strong promoter. | 12-27-2012 |